PMV Pharmaceuticals (PMVP) Competitors $1.37 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PMVP vs. ITOS, AQST, IMMP, NGNE, OLMA, ATYR, RZLT, AVIR, CMPX, and CGCShould you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include iTeos Therapeutics (ITOS), Aquestive Therapeutics (AQST), Immutep (IMMP), Neurogene (NGNE), Olema Pharmaceuticals (OLMA), Atyr PHARMA (ATYR), Rezolute (RZLT), Atea Pharmaceuticals (AVIR), Compass Therapeutics (CMPX), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. PMV Pharmaceuticals vs. iTeos Therapeutics Aquestive Therapeutics Immutep Neurogene Olema Pharmaceuticals Atyr PHARMA Rezolute Atea Pharmaceuticals Compass Therapeutics Canopy Growth PMV Pharmaceuticals (NASDAQ:PMVP) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation. Which has preferable valuation & earnings, PMVP or ITOS? PMV Pharmaceuticals has higher earnings, but lower revenue than iTeos Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPMV PharmaceuticalsN/AN/A-$68.96M-$1.00-1.37iTeos Therapeutics$12.60M23.19-$112.64M-$3.15-2.54 Is PMVP or ITOS more profitable? iTeos Therapeutics' return on equity of -20.11% beat PMV Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets PMV PharmaceuticalsN/A -24.20% -21.67% iTeos Therapeutics N/A -20.11%-17.50% Does the MarketBeat Community prefer PMVP or ITOS? iTeos Therapeutics received 19 more outperform votes than PMV Pharmaceuticals when rated by MarketBeat users. Likewise, 79.25% of users gave iTeos Therapeutics an outperform vote while only 62.16% of users gave PMV Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPMV PharmaceuticalsOutperform Votes2362.16% Underperform Votes1437.84% iTeos TherapeuticsOutperform Votes4279.25% Underperform Votes1120.75% Which has more volatility and risk, PMVP or ITOS? PMV Pharmaceuticals has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Does the media favor PMVP or ITOS? In the previous week, iTeos Therapeutics had 5 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 5 mentions for iTeos Therapeutics and 0 mentions for PMV Pharmaceuticals. iTeos Therapeutics' average media sentiment score of 0.67 beat PMV Pharmaceuticals' score of 0.00 indicating that iTeos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment PMV Pharmaceuticals Neutral iTeos Therapeutics Positive Do insiders and institutionals believe in PMVP or ITOS? 90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 12.5% of iTeos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer PMVP or ITOS? PMV Pharmaceuticals currently has a consensus price target of $5.50, indicating a potential upside of 301.46%. iTeos Therapeutics has a consensus price target of $22.25, indicating a potential upside of 178.13%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe PMV Pharmaceuticals is more favorable than iTeos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20iTeos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryiTeos Therapeutics beats PMV Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMVP vs. The Competition Export to ExcelMetricPMV PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.90M$6.23B$5.21B$9.15BDividend YieldN/A2.94%5.13%4.03%P/E Ratio-1.379.5488.0817.36Price / SalesN/A309.511,243.2778.03Price / CashN/A61.4443.7535.97Price / Book0.316.055.314.79Net Income-$68.96M$154.90M$122.62M$225.00M7 Day Performance-1.44%-0.32%0.61%2.62%1 Month Performance-8.67%0.43%2.56%3.81%1 Year Performance-14.91%3.08%25.79%20.10% PMV Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMVPPMV Pharmaceuticals2.2399 of 5 stars$1.37flat$5.50+301.5%-14.9%$70.90MN/A-1.3750Positive NewsITOSiTeos Therapeutics4.0348 of 5 stars$7.80+0.5%$22.25+185.3%-24.2%$284.97M$35M-2.4890AQSTAquestive Therapeutics1.8966 of 5 stars$3.11+1.0%$11.00+253.7%+27.0%$283.56M$58.90M-6.91160Short Interest ↑IMMPImmutep1.3999 of 5 stars$1.94-3.5%$8.50+338.1%-14.6%$282.38M$5.14M0.002,021NGNENeurogene2.7302 of 5 stars$18.81-3.9%$60.83+223.4%-44.8%$279.42M$925,000.000.0090Gap DownOLMAOlema Pharmaceuticals2.6547 of 5 stars$4.84-4.0%$27.00+457.9%-49.8%$277.32MN/A-2.2170News CoveragePositive NewsATYRAtyr PHARMA2.9106 of 5 stars$3.29-6.8%$19.25+485.1%N/A$276.17M$235,000.00-3.5053Positive NewsRZLTRezolute3.5053 of 5 stars$4.75-3.1%$24.13+407.9%+387.0%$275.23MN/A-3.7440AVIRAtea Pharmaceuticals3.8713 of 5 stars$3.20-2.1%$6.88+115.0%-5.6%$270.28M$351.37M-1.5570Short Interest ↓Gap UpCMPXCompass Therapeutics3.163 of 5 stars$1.95+10.2%$11.80+505.1%+87.1%$268.30M$850,000.00-5.2720Short Interest ↑News CoverageCGCCanopy Growth3.2075 of 5 stars$2.39-2.4%$3.50+46.4%-50.1%$260.37M$280.50M-0.483,150 Related Companies and Tools Related Companies iTeos Therapeutics Alternatives Aquestive Therapeutics Alternatives Immutep Alternatives Neurogene Alternatives Olema Pharmaceuticals Alternatives Atyr PHARMA Alternatives Rezolute Alternatives Atea Pharmaceuticals Alternatives Compass Therapeutics Alternatives Canopy Growth Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PMVP) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump secret stock already up 339% In this video, you’ll also get nine other Trump-connected investments… All of which we believe could have a...Porter & Company | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
